Navigation Links
Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
Date:11/10/2008

ods sold 136.5 162.0

Rental expenses 52.9 50.6

Total cost of revenues 189.4 212.6

Gross profit

Capital sales 93.0 114.6

Rental revenues 59.0 44.8

Total gross profit 152.0 159.4

As a percentage of sales 44.5% 42.8%

Operating expense 126.3 125.7

As a percentage of sales 37.0% 33.8%

Litigation and special (charges)/credits, net (2.3) 1.6

Operating profit 23.4 35.3

Other income/(expense), net (2.8) (2.2)

Income tax expense (1) 8.2 8.7

Income from continuing operations $12.4 $24.4

Diluted earnings per share:

Earnings per share from continuing

operations $0.20 $0.39

Average common shares outstanding -

diluted (thousands) 62,403 62,393

Dividends per common share $0.2850 $0.2850

Consolidated Cash Flows from

Operations (2)

Cash flow from operations $120.1 $88.5

Less: capital expenditures (26.0) (34.6)

Consolidated free cash flow $94.1 $53.9

Cash and cash equivalents $125.5 $81.5

Investment securities (3) $164.3 $112.8

Hill-Rom Capital Expenditures $23.7
'/>"/>

SOURCE Hill-Rom Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
2. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
3. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
4. BMP Sunstone Reports Third Quarter 2008 Financial Results
5. Endocare Reports Financial Results for Third Quarter 2008
6. Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs
7. Isis Reports Financial Results and Highlights for Third Quarter of 2008
8. OncoGenex Reports Third Quarter Financial Results
9. American Oriental Bioengineering Reports Third Quarter 2008 Financial Results
10. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
11. Dendreon Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/25/2015)... SHANGHAI , Aug. 25, 2015   WuXi ... open-access R&D capability and technology platform company serving the ... Holdings Ltd. ("Lee,s Pharm," Hong Kong Exchange Stock Code: ... Hong Kong with 20 years of operations ... the two companies have signed an agreement whereby WuXi,s ...
(Date:8/25/2015)... 2015 Human Longevity, Inc. (HLI), the genomics-based, technology-driven ... joined the company as Chief Operating Officer. Winham, who brings ... technical experience, will report directly to HLI,s CEO, J. ... role as COO, Winham will be responsible for managing all ... all facility operations. HLI currently has three locations in ...
(Date:8/25/2015)... Fla. , Aug. 25, 2015  InformedDNA, ... today that it has been awarded Certification in ... Assurance (NCQA). NCQA is a ... accredits and certifies a wide range of healthcare ... key areas of performance. "Our achievement ...
(Date:8/25/2015)... , Aug. 25, 2015   CSL Behring ... in its Phase II/III clinical study evaluating the pharmacokinetics ... protein linking coagulation factor VIIa with albumin (rVIIa-FP) for ... B who have developed an inhibitor to factor VIII ... approximately 54 male patients, the first of whom was ...
Breaking Biology Technology:WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3Human Longevity, Inc. Hires Life Sciences Leader, Mark Winham, as Chief Operating Officer 2InformedDNA Achieves NCQA Utilization Management Certification 2CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 2CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 3CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 4
... 24 hours a day now that a new company has ... Web site MusicMadeInMadison.com plays more than 450 songs ... Daedalus Burn, Infinite Helix and They Drive By Night. Founded ... is to help both the circulation of the artists and ...
... succeed both personally and professionally. , ,You should make sure ... business world and your community. Once these partnerships are built, ... your needs and goals. At the same, make sure you ... , ,Relationships need to be mutually beneficial for all parties. ...
... Venture Forum was held two weeks ago in Los ... to an audience of several hundred venture capital, strategic ... interest to Midwest technology entrepreneurs as there were several ... forum is organized by the Larta Institute. Based in ...
Cached Biology Technology:Don't forget building relationships when building business 2Don't forget building relationships when building business 3Don't forget building relationships when building business 4Midwest fares surprisingly well at Venture Forum in Los Angeles 2Midwest fares surprisingly well at Venture Forum in Los Angeles 3Midwest fares surprisingly well at Venture Forum in Los Angeles 4
(Date:8/20/2015)... PLEASANTON, Calif. , Aug. 20, 2015 /PRNewswire/ ... focused on consumers that are active and healthy. ... used in the hospital environment to help improve ... released a video from the Wearable Technologies ... MD discussed new applications for wearables in healthcare.    ...
(Date:8/18/2015)... Aug. 17, 2015 Research and Markets ... the "Global Biometric Authentication & Identification Market: ... & Forecast, 2015-2020" report to their offering. ... identification systems market is expected to grow at ... 2020 and generate over $25 billion (approximately) by ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... paper authored by San Diego Zoo Institute for Conservation ... the endangered California condor in the wild are human ... juvenile and adult birds. , The study documents ... sitesCalifornia, Arizona and Baja, California, Mexicofrom the inception of ...
... by Kasturi Haldar and Souvik Bhattacharjee of the University ... has made a fundamental discovery in understanding how malaria ... parasites target proteins to the surface of the red ... vessels. Strategies that prevent this host-targeting process will block ...
... for the Study of Bioethical Issues will hold a ... Following its report on Human Subjects Protections, the ... children, whole genome sequencing and neuroethics. Medical ... Health and Human Services Kathleen Sebelius asked the Commission ...
Cached Biology News:Scientific paper shows California condor still threatened by human activities 2Notre Dame researchers report fundamental malaria discovery 2Bioethics commission to meet in February in San Francisco 2
... Perhaps sheer in-house demand is causing shortages ... precious antibody. This can cause unwanted distractions, problems ... royalties for your hard work and endeavour! Bring ... up and market it internationally. We work under ...
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
Topoisomerase I...
... Topoisomerase I from vaccinia virus is ... both positive and negative superhelical turns (also ... closed DNA. The product of the reaction ... fewer positive or negative superhelical turns. DNA ...
Biology Products: